SVRA
Savara Inc.
$5.78
$0.00(0.00%)
35
Overall
50
Value
20
Tech
--
Quality
Market Cap
$686.16M
Volume
1.29M
52W Range
$1.89 - $7.01
Target Price
$10.81
Company Overview
| Mkt Cap | $686.16M | Price | $5.78 |
| Volume | 1.29M | Change | +0.00% |
| P/E Ratio | -7.2 | Open | $5.60 |
| Revenue | -- | Prev Close | $5.78 |
| Net Income | $-95.9M | 52W Range | $1.89 - $7.01 |
| Div Yield | N/A | Target | $10.81 |
| Overall | 35 | Value | 50 |
| Quality | -- | Technical | 20 |
No chart data available
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Edwards Lifesciences (EW)
Howard Kim•9 days ago
Savara (SVRA) Gets a Buy from LifeSci Capital
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
Analysts Are Bullish on Top Healthcare Stocks: Savara (SVRA), Erasca (ERAS)
Catie Powers•23 days ago
LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SVRA | $5.78 | 0% | 1.29M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |